Psychopharmacy Flashcards
Antipsychotics - dopamine pathways
Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular
Antipsychotics - dopamine hypothesis
1) hyperactivity of the mesolimbic dopamine pathways cause positive symptoms of schizophrenia
2) deficiency of dopamine in the nigrostriatal pathway accounts for negative and cognitive symptoms of schizophrenia
Antipsychotics - mechanism of action
Block dopamine receptors in the mesolimbic pathway
Antipsychotics - typical antipsychotic examples
Haloperidol
Flupentixol
Chlorpromazine hydrochloride
Antipsychotics - atypical antipsychotic examples
Clozapine Quetiapine Olanzapine Aripiprazole Risperidone
Antipsychotics - indications
Schizophrenia
Schizoid personality disorder
Bipolar affective disorder
Antipsychotics - movement disorder adverse effects
Acute dystonia (e.g. torticollis) Tardive dyskinesia (hyperkinetic involuntary movements) Akathisia (restlessness, tension) Pseudoparkinsonism (tremor, rigidity, bradykinesia)
Antipsychotics - adverse autonomic effects
Antiadrenergic
- QTc prolonged and arrhythmias (torsade des pointes)
Anticholinergic
- dry mouth, blurred vision, constipation and urine trouble
Antipsychotics - adverse effects
Movement disorders Autonomic effects Neuroleptic malignant syndrome Convulsant activity Pigmentation Metabolic effects - weight gain - endocrine (hyperprolactinaemia, decreased libido, sexual dysfunction and menstrual irregularities) Hypersensitivity - cholestatic jaundice - skin reactions (urticaria/eczema)
Clozapine - indications
Treatment resistant schizophrenia
Clozapine - side effects
Less extrapyramidal side effects than typical antipsychotics
Agranulocytosis
Weight gain
Clozapine - smoking risk
Smoking reduces the concentration of clozapine in the plasma
Smoking cessation causes an increase in clozapine levels in the plasma
- can cause dose related side effects (sedation, dizziness, hypersalivation, tachycardia, postural hypotension, constipation and seziures)
Mood stabilisers - available in UK
Lithium
Carbamazepine
Valproate
Mood stabilisers - indications
Acute mania/hypomania in bipolar
Prophylaxis in bipolar and schizoaffective disorders
Prophylaxis in recurrent depressive illness
Augment antidepressant therapy in acute depressive illness
Treating depression in bipolar
Mood stabilisers - what are the expected effects on the patient when using mood stabilisers
Decreased mental and physical overactivity
Improves psychotic features
Prevents exhaustion, sleep deprivation and poor fluid intake